Carvedilol protects against the renal mitochondrial toxicity induced by cisplatin in rats

Mitochondrion

Volumn 10, Issue 1, 2010, Pages 46-53

  Carvalho Rodrigues, M A ^a   Rodrigues, J L ^a   Martins, N M ^a   Barbosa, F ^a   Curti, C ^a   Santos, N A G ^a   Santos, A C ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Antioxidant; Carvedilol; Cisplatin; Cytoprotection; Mitochondria; Nephrotoxicity

Indexed keywords

ADENOSINE TRIPHOSPHATE; CARVEDILOL; CISPLATIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; CALCIUM TRANSPORT; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG MECHANISM; MALE; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRIAL RESPIRATION; MITOCHONDRIAL TOXICITY; NEPHROTOXICITY; NONHUMAN; OXIDATIVE PHOSPHORYLATION; PRIORITY JOURNAL; RAT; RENAL PROTECTION; UREA NITROGEN BLOOD LEVEL;

ANIMALS; ANTIHYPERTENSIVE AGENTS; ANTINEOPLASTIC AGENTS; ANTIOXIDANTS; CALCIUM; CARBAZOLES; CISPLATIN; KIDNEY; KIDNEY DISEASES; MALE; MEMBRANE POTENTIALS; MITOCHONDRIA; OXYGEN CONSUMPTION; PROPANOLAMINES; RATS; RATS, WISTAR;

RATTUS;

EID: 70450273275     PISSN: 15677249     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mito.2009.09.001     Document Type: Article

References (59)

1. Ali B.H., and Al Moundhri M.S. Agents ameliorating or augmenting the nephrotoxicity of cisplatin and other platinum compounds: a review of some recent research. Food Chem. Toxicol. 44 (2006) 1173-1183
2. Appenroth D., Frob S., Kersten L., Splinter F.K., and Winnefeld K. Protective effects of vitamin E and C on cisplatin nephrotoxicity in developing rats. Arch. Toxicol. 71 (1997) 677-683
3. Armstrong S.C. Anti-oxidants and apoptosis: attenuation of doxorubicin induced cardiomyopathy by carvedilol. J. Mol. Cell Cardiol. 37 (2004) 817-821
4. Baliga R., Zhang Z., Baliga M., Ueda N., and Shah S.V. In vitro and in vivo evidence suggesting a role for iron in cisplatin-induced nephrotoxicity. Kidney Int. 53 (1998) 394-401
5. Berry M.N., Edwards A.M., and Barrit G.J. High-yield preparation of isolated hepatocytes from rat liver. In: Burdon R.H., and Knippenberg P.H. (Eds). Laboratory Techniques in Biochemistry and Molecular Biology Isolated Hepatocytes Preparation, Properties and Applications (1991), Elsevier, Amsterdan 15-58
6. Brady H.R., Kone B.C., Stromski M.E., Zeidel M.L., Giebisch G., and Gullans S.R. Mitochondrial injury: an early event in cisplatin toxicity to renal proximal tubules. Am. J. Physiol. 258 (1990) F1181-1187
7. Cardoso S.M., Pereira C., and Oliveira R. Mitochondrial function is differentially affected upon oxidative stress. Free Radical Biol. Med. 26 (1999) 3-13
8. Chance B., and Williams G.R. The respiratory chain and oxidative phosphorylation. Adv. Enzymol. Relat. Sub. Biochem. 17 (1956) 65-134
9. Chang B., Nishikawa M., Sato E., Utsumi K., and Inoue M. l-Carnitine inhibits cisplatin-induced injury of the kidney and small intestine. Arch. Biochem. Biophys. 405 (2002) 55-64
10. Chipuk J.E., Kuwana T., Bouchier-Hayes L., Droin N.M., Newmeyer D.D., Schuler M., and Green D.R. Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. Science 303 (2004) 1010-1014
11. Cvitkovic E. Cumulative toxicities from cisplatin therapy and current cytoprotective measures. Cancer Treat. Rev. 24 (1998) 265-281
12. Dandona P., Ghanim H., and Brooks D.P. Antioxidant activity of carvedilol in cardiovascular disease. J. Hypertens. 25 (2007) 731-741
13. Dickey D.T., Muldoon L.L., Doolittle N.D., Peterson D.R., Kraemer D.F., and Neuwelt E.A. Effect of N-acetylcysteine route of administration on chemoprotection against cisplatin-induced toxicity in rat models. Cancer Chemother. Pharmacol. 62 (2008) 235-241
14. Droge W. Free radicals in the physiological control of cell function. Physiol. Rev. 82 (2002) 47-95
15. Emaus R.K., Grunwald R., and Lemasters J.J. Rhodamine 123 as a probe of transmembrane potential in isolated rat-liver mitochondria: spectral and metabolic properties. Biochim. Biophys. Acta 850 (1986) 436-448
16. Gamal el-Din A.M., and Al-Bekairi A.M. Carvedilol, a beta adrenoceptor blocker with antioxidative potential, attenuates cisplatin-induced nephrtotoxicity in rats. J. Appl. Sci. Res. 2 (2006) 331-335
17. Gemba M., Nakatani E., Teramoto M., and Nakano S. Effect of cisplatin on calcium uptake by rat kidney cortical mitochondria. Toxicol. Lett. 38 (1987) 291-297
18. Goulle J.P., Mahieu L., Castermant J., Neveu N., Bonneau L., Laine G., Bouige D., and Lacroix C. Metal and metalloid multi-elementary ICP-MS validation in whole blood, plasma, urine and hair. Reference values. Forensic. Sci. Int. 153 (2005) 39-44
19. Hanigan M.H., and Devarajan P. Cisplatin nephrotoxicity: molecular mechanisms. Cancer Ther. 1 (2003) 47-61
20. Hayashi T., Saitou Y., Nose K., Nishioka T., Ishii T., and Uemura H. Efficacy of carvedilol for ischemia/reperfusion-induced oxidative renal injury in rats. Transplant. Proc. 40 (2008) 2139-2141
21. Iguchi T., Nishikawa M., Chang B., Muroya O., Sato E.F., Nakatani T., and Inoue M. Edaravone inhibits acute renal injury and cyst formation in cisplatin-treated rat kidney. Free Radical Res. 38 (2004) 333-341
22. Jiang M., and Dong Z. Regulation and pathological role of p53 in cisplatin nephrotoxicity. J. Pharmacol. Exp. Ther. 327 (2008) 300-307
23. Jiang M., Pabla N., Murphy R.F., Yang T., Yin X.M., Degenhardt K., White E., and Dong Z. Nutlin-3 protects kidney cells during cisplatin therapy by suppressing Bax/Bak activation. J. Biol. Chem. 282 (2007) 2636-2645
24. Jiang M., Wei Q., Pabla N., Dong G., Wang C.Y., Yang T., Smith S.B., and Dong Z. Effects of hydroxyl radical scavenging on cisplatin-induced p53 activation, tubular cell apoptosis and nephrotoxicity. Biochem. Pharmacol. 73 (2007) 1499-1510
25. Jing X.B., Cai X.B., Hu H., Chen S.Z., Chen B.M., and Cai J.Y. Reactive oxygen species and mitochondrial membrane potential are modulated during CDDP-induced apoptosis in EC-109 cells. Biochem. Cell Biol. 85 (2007) 265-271
26. Kintzel P.E. Anticancer drug-induced kidney disorders. Drug Safety 24 (2001) 19-38
27. Koyner J.L., Sher Ali R., and Murray P.T. Antioxidants. Do they have a place in the prevention or therapy of acute kidney injury?. Nephron Exp. Nephrol. 109 (2008) e109-117
28. Kroning R., Lichtenstein A.K., and Nagami G.T. Sulfur-containing amino acids decrease cisplatin cytotoxicity and uptake in renal tubule epithelial cell lines. Cancer Chemother. Pharmacol. 45 (2000) 43-49
29. Kruidering M., Van de Water B., de Heer E., Mulder G.J., and Nagelkerke J.F. Cisplatin-induced nephrotoxicity in porcine proximal tubular cells: mitochondrial dysfunction by inhibition of complexes I to IV of the respiratory chain. J. Pharmacol. Exp. Ther. 280 (1997) 638-649
30. Kumar K.V., Shifow A.A., Naidu M.U., and Ratnakar K.S. Carvedilol: a beta blocker with antioxidant property protects against gentamicin-induced nephrotoxicity in rats. Life Sciences 66 (2000) 2603-2611
31. Links M., and Lewis C. Chemoprotectants: a review of their clinical pharmacology and therapeutic efficacy. Drugs 57 (1999) 293-308
32. Masubuchi Y., Suda C., and Horie T. Involvement of mitochondrial permeability transition in acetaminophen-induced liver injury in mice. J. Hepatol. 42 (2005) 110-116
33. Nisar S., and Feinfeld D.A. N-acetylcysteine as salvage therapy in cisplatin nephrotoxicity. Renal Failure 24 (2002) 529-533
34. Noguchi N., Nishino K., and Niki E. Antioxidant action of the antihypertensive drug, carvedilol, against lipid peroxidation. Biochem. Pharmacol. 59 (2000) 1069-1076
35. O'Connor J.E., Vargas J.L., Kimler B.F., Hernandez-Yago J., and Grisolia S. Use of rhodamine 123 to investigate alterations in mitochondrial activity in isolated mouse liver mitochondria. Biochem. Biophys. Res. Commun. 151 (1988) 568-573
36. Oliveira P.J., Bjork J.A., Santos M.S., Leino R.L., Froberg M.K., Moreno A.J., and Wallace K.B. Carvedilol-mediated antioxidant protection against doxorubicin-induced cardiac mitochondrial toxicity. Toxicol. Appl. Pharmacol. 200 (2004) 159-168
37. Pabla N., and Dong Z. Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney Int. 73 (2008) 994-1007
38. Park S.A., Park H.J., Lee B.I., Ahn Y.H., Kim S.U., and Choi K.S. Bcl-2 blocks cisplatin-induced apoptosis by suppression of ERK-mediated p53 accumulation in B104 cells. Brain Res. Mol. Brain Res. 93 (2001) 18-26
39. Pedersen P.L., Greenawalt J.W., Reynafarje B., Hullihen J., Decker G.L., Soper J.W., and Bustamente E. Preparation and characterization of mitochondria and submitochondrial particles of rat liver and liver-derived tissues. Methods Cell Biol. 20 (1978) 411-481
40. Reed J.C., Jurgensmeier J.M., and Matsuyama S. Bcl-2 family proteins and mitochondria. Biochim. Biophys. Acta 1366 (1998) 127-137
41. Santos A.C., Uyemura S.A., Santos N.A., Mingatto F.E., and Curti C. Hg(II)-induced renal cytotoxicity: in vitro and in vivo implications for the bioenergetic and oxidative status of mitochondria. Mol. Cell. Biochem. 177 (1997) 53-59
42. Santos N.A., Catao C.S., Martins N.M., Curti C., Bianchi M.L., and Santos A.C. Cisplatin-induced nephrotoxicity is associated with oxidative stress, redox state unbalance, impairment of energetic metabolism and apoptosis in rat kidney mitochondria. Arch. Toxicol. 81 (2007) 495-504
43. Santos N.A., Bezerra C.S., Martins N.M., Curti C., Bianchi M.L., and Santos A.C. Hydroxyl radical scavenger ameliorates cisplatin-induced nephrotoxicity by preventing oxidative stress, redox state unbalance, impairment of energetic metabolism and apoptosis in rat kidney mitochondria. Cancer Chemother. Pharmacol. 61 (2008) 145-155
44. Sastry J., and Kellie S.J. Severe neurotoxicity, ototoxicity and nephrotoxicity following high-dose cisplatin and amifostine. Pediatr. Hematol. Oncol. 22 (2005) 441-445
45. Scarpa A. Measurements of cation transport with metallochromic indicators. Methods Enzymol. 56 (1979) 301-338
46. Servais H., Ortiz A., Devuyst O., Denamur S., Tulkens P.M., and Mingeot-Leclercq M.P. Renal cell apoptosis induced by nephrotoxic drugs: cellular and molecular mechanisms and potential approaches to modulation. Apoptosis 13 (2008) 11-32
47. Sheikh-Hamad D., Timmins K., and Jalali Z. Cisplatin-induced renal toxicity: possible reversal by N-acetylcysteine treatment. J. Am. Soc. Nephrol. 8 (1997) 1640-1644
48. Singh G. A possible cellular mechanism of cisplatin-induced nephrotoxicity. Toxicology 58 (1989) 71-80
49. Singh D., Chander V., and Chopra K. Carvedilol, an antihypertensive drug with antioxidant properties, protects against glycerol-induced acute renal failure. Am. J. Nephrol. 23 (2003) 415-421
50. Singh D., Chander V., and Chopra K. Carvedilol attenuates ischemia-reperfusion-induced oxidative renal injury in rats. Fundam. Clin. Pharmacol. 18 (2004) 627-634
51. Somani S.M., Husain K., Whitworth C., Trammell G.L., Malafa M., and Rybak L.P. Dose-dependent protection by lipoic acid against cisplatin-induced nephrotoxicity in rats: antioxidant defense system. Pharmacol. Toxicol. 86 (2000) 234-241
52. Spallarossa P., Garibaldi S., Altieri P., Fabbi P., Manca V., Nasti S., Rossettin P., Ghigliotti G., Ballestrero A., Patrone F., Barsotti A., and Brunelli C. Carvedilol prevents doxorubicin-induced free radical release and apoptosis in cardiomyocytes in vitro. J. Mol. Cell. Cardiol. 37 (2004) 837-846
53. Sueishi K., Mishima K., Makino K., Itoh Y., Tsuruya K., Hirakata H., and Oishi R. Protection by a radical scavenger edaravone against cisplatin-induced nephrotoxicity in rats. Eur. J. Pharmacol. 451 (2002) 203-208
54. Tarladacalisir Y.T., Kanter M., and Uygun M. Protective effects of vitamin C on cisplatin-induced renal damage: a light and electron microscopic study. Renal Failure 30 (2008) 1-8
55. Tsuruya K., Tokumoto M., Ninomiya T., Hirakawa M., Masutani K., Taniguchi M., Fukuda K., Kanai H., Hirakata H., and Iida M. Antioxidant ameliorates cisplatin-induced renal tubular cell death through inhibition of death receptor-mediated pathways. Am. J. Physiol. Renal Physiol. 285 (2003) F208-218
56. Turrens J.F. Mitochondrial formation of reactive oxygen species. J. Physiol. 552 (2003) 335-344
57. Weijl N.I., Cleton F.J., and Osanto S. Free radicals and antioxidants in chemotherapy-induced toxicity. Cancer Treat. Rev. 23 (1997) 209-240
58. Yao X., Panichpisal K., Kurtzman N., and Nugent K. Cisplatin nephrotoxicity: a review. Am. J. Med. Sci. 334 (2007) 115-124
59. Yue T.L., Cheng H.Y., Lysko P.G., McKenna P.J., Feuerstein R., Gu J.L., Lysko K.A., Davis L.L., and Feuerstein G. Carvedilol, a new vasodilator and beta adrenoceptor antagonist, is an antioxidant and free radical scavenger. J. Pharmacol. Exp. Ther. 263 (1992) 92-98